Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats

B. E. Pérez-Guillé, F. Villegas-Alvarez, M. A. Jimenez-Bravo, R. E. Soriano-Rosales, J. F. Gonzalez-Zamora, A. Toledo-Lopez, G. A. Camacho-Vieyra, A. Guillé-Pérez, I. Lares-Asseff, M. G. Pérez-Guillé

Research output: Contribution to journalArticle

Abstract

© 2015 Asian Network for Scientific Information. Portacaval shunts are commonly used to prevent gastroesophageal variceal bleeding secondary to portal hypertension. Ammonia encephalopathy is a common complication and it’s management includes antibiotics such as metronidazole, neomycin and recently, rifaximin. Metronidazole is often used in this context but its pharm acokinetics may be altered in these patients. Compare the pharmacokinetic parameters of two groups of rats, one of them after one year of having undergone mesocaval shunt. A randomized, experimental, prospective study in twenty adult male Lewis rats divided into two groups. The first group underwent mesocaval shunt and the other was the control group. Analyses of the following parameters were performed in both groups: (1) Pharmacokinetics of metronidazole by high-performance liquid chromatography, (2) Transaminase levels and (3) Body and liver weight. Differences between the MCS group and the control group were found for the pharmacokinetic parameters: Cm ax (p = 0.004), Ka (p = 0.009), Ka tl/2 (p = 0.007), Vd (p = 0.01), AUC (p = 0.05) and tmax (p = 0.01) and in ALT levels (p = 0.03) and liver weight (p = 0.00). The results obtained in this experimental model during one year of mesocaval shunt led us to suggest that metronidazole dosage should be decreased, without altering the administration schedule, because the drug levels reached in the mesocaval shunt group caused the animals to behave as if they had been given higher doses.
Original languageAmerican English
Pages (from-to)143-147
Number of pages5
JournalInternational Journal of Pharmacology
DOIs
StatePublished - 1 Jan 2015

Fingerprint

Metronidazole
Pharmacokinetics
rifaximin
Drug Administration Schedule
Surgical Portacaval Shunt
Control Groups
Neomycin
Information Services
Liver
Brain Diseases
Portal Hypertension
Transaminases
Ammonia
Area Under Curve
Theoretical Models
High Pressure Liquid Chromatography
Body Weight
Prospective Studies
Hemorrhage
Anti-Bacterial Agents

Cite this

Pérez-Guillé, B. E., Villegas-Alvarez, F., Jimenez-Bravo, M. A., Soriano-Rosales, R. E., Gonzalez-Zamora, J. F., Toledo-Lopez, A., ... Pérez-Guillé, M. G. (2015). Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats. International Journal of Pharmacology, 143-147. https://doi.org/10.3923/ijp.2015.143.147
Pérez-Guillé, B. E. ; Villegas-Alvarez, F. ; Jimenez-Bravo, M. A. ; Soriano-Rosales, R. E. ; Gonzalez-Zamora, J. F. ; Toledo-Lopez, A. ; Camacho-Vieyra, G. A. ; Guillé-Pérez, A. ; Lares-Asseff, I. ; Pérez-Guillé, M. G. / Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats. In: International Journal of Pharmacology. 2015 ; pp. 143-147.
@article{1ce22c73b58744c99aa0449dbbf5a11e,
title = "Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats",
abstract = "{\circledC} 2015 Asian Network for Scientific Information. Portacaval shunts are commonly used to prevent gastroesophageal variceal bleeding secondary to portal hypertension. Ammonia encephalopathy is a common complication and it’s management includes antibiotics such as metronidazole, neomycin and recently, rifaximin. Metronidazole is often used in this context but its pharm acokinetics may be altered in these patients. Compare the pharmacokinetic parameters of two groups of rats, one of them after one year of having undergone mesocaval shunt. A randomized, experimental, prospective study in twenty adult male Lewis rats divided into two groups. The first group underwent mesocaval shunt and the other was the control group. Analyses of the following parameters were performed in both groups: (1) Pharmacokinetics of metronidazole by high-performance liquid chromatography, (2) Transaminase levels and (3) Body and liver weight. Differences between the MCS group and the control group were found for the pharmacokinetic parameters: Cm ax (p = 0.004), Ka (p = 0.009), Ka tl/2 (p = 0.007), Vd (p = 0.01), AUC (p = 0.05) and tmax (p = 0.01) and in ALT levels (p = 0.03) and liver weight (p = 0.00). The results obtained in this experimental model during one year of mesocaval shunt led us to suggest that metronidazole dosage should be decreased, without altering the administration schedule, because the drug levels reached in the mesocaval shunt group caused the animals to behave as if they had been given higher doses.",
author = "P{\'e}rez-Guill{\'e}, {B. E.} and F. Villegas-Alvarez and Jimenez-Bravo, {M. A.} and Soriano-Rosales, {R. E.} and Gonzalez-Zamora, {J. F.} and A. Toledo-Lopez and Camacho-Vieyra, {G. A.} and A. Guill{\'e}-P{\'e}rez and I. Lares-Asseff and P{\'e}rez-Guill{\'e}, {M. G.}",
year = "2015",
month = "1",
day = "1",
doi = "10.3923/ijp.2015.143.147",
language = "American English",
pages = "143--147",
journal = "International Journal of Pharmacology",
issn = "1811-7775",
publisher = "Asian Network for Scientific Information",

}

Pérez-Guillé, BE, Villegas-Alvarez, F, Jimenez-Bravo, MA, Soriano-Rosales, RE, Gonzalez-Zamora, JF, Toledo-Lopez, A, Camacho-Vieyra, GA, Guillé-Pérez, A, Lares-Asseff, I & Pérez-Guillé, MG 2015, 'Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats', International Journal of Pharmacology, pp. 143-147. https://doi.org/10.3923/ijp.2015.143.147

Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats. / Pérez-Guillé, B. E.; Villegas-Alvarez, F.; Jimenez-Bravo, M. A.; Soriano-Rosales, R. E.; Gonzalez-Zamora, J. F.; Toledo-Lopez, A.; Camacho-Vieyra, G. A.; Guillé-Pérez, A.; Lares-Asseff, I.; Pérez-Guillé, M. G.

In: International Journal of Pharmacology, 01.01.2015, p. 143-147.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats

AU - Pérez-Guillé, B. E.

AU - Villegas-Alvarez, F.

AU - Jimenez-Bravo, M. A.

AU - Soriano-Rosales, R. E.

AU - Gonzalez-Zamora, J. F.

AU - Toledo-Lopez, A.

AU - Camacho-Vieyra, G. A.

AU - Guillé-Pérez, A.

AU - Lares-Asseff, I.

AU - Pérez-Guillé, M. G.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - © 2015 Asian Network for Scientific Information. Portacaval shunts are commonly used to prevent gastroesophageal variceal bleeding secondary to portal hypertension. Ammonia encephalopathy is a common complication and it’s management includes antibiotics such as metronidazole, neomycin and recently, rifaximin. Metronidazole is often used in this context but its pharm acokinetics may be altered in these patients. Compare the pharmacokinetic parameters of two groups of rats, one of them after one year of having undergone mesocaval shunt. A randomized, experimental, prospective study in twenty adult male Lewis rats divided into two groups. The first group underwent mesocaval shunt and the other was the control group. Analyses of the following parameters were performed in both groups: (1) Pharmacokinetics of metronidazole by high-performance liquid chromatography, (2) Transaminase levels and (3) Body and liver weight. Differences between the MCS group and the control group were found for the pharmacokinetic parameters: Cm ax (p = 0.004), Ka (p = 0.009), Ka tl/2 (p = 0.007), Vd (p = 0.01), AUC (p = 0.05) and tmax (p = 0.01) and in ALT levels (p = 0.03) and liver weight (p = 0.00). The results obtained in this experimental model during one year of mesocaval shunt led us to suggest that metronidazole dosage should be decreased, without altering the administration schedule, because the drug levels reached in the mesocaval shunt group caused the animals to behave as if they had been given higher doses.

AB - © 2015 Asian Network for Scientific Information. Portacaval shunts are commonly used to prevent gastroesophageal variceal bleeding secondary to portal hypertension. Ammonia encephalopathy is a common complication and it’s management includes antibiotics such as metronidazole, neomycin and recently, rifaximin. Metronidazole is often used in this context but its pharm acokinetics may be altered in these patients. Compare the pharmacokinetic parameters of two groups of rats, one of them after one year of having undergone mesocaval shunt. A randomized, experimental, prospective study in twenty adult male Lewis rats divided into two groups. The first group underwent mesocaval shunt and the other was the control group. Analyses of the following parameters were performed in both groups: (1) Pharmacokinetics of metronidazole by high-performance liquid chromatography, (2) Transaminase levels and (3) Body and liver weight. Differences between the MCS group and the control group were found for the pharmacokinetic parameters: Cm ax (p = 0.004), Ka (p = 0.009), Ka tl/2 (p = 0.007), Vd (p = 0.01), AUC (p = 0.05) and tmax (p = 0.01) and in ALT levels (p = 0.03) and liver weight (p = 0.00). The results obtained in this experimental model during one year of mesocaval shunt led us to suggest that metronidazole dosage should be decreased, without altering the administration schedule, because the drug levels reached in the mesocaval shunt group caused the animals to behave as if they had been given higher doses.

U2 - 10.3923/ijp.2015.143.147

DO - 10.3923/ijp.2015.143.147

M3 - Article

SP - 143

EP - 147

JO - International Journal of Pharmacology

JF - International Journal of Pharmacology

SN - 1811-7775

ER -

Pérez-Guillé BE, Villegas-Alvarez F, Jimenez-Bravo MA, Soriano-Rosales RE, Gonzalez-Zamora JF, Toledo-Lopez A et al. Long-term effects of mesocaval shunt on the pharmacokinetic parameters of metronidazole in lewis rats. International Journal of Pharmacology. 2015 Jan 1;143-147. https://doi.org/10.3923/ijp.2015.143.147